Advertisement
"Continued expansion of local capabilities combined with an integratedglobal clinical pharmacology presence has been a cornerstone of PAREXEL'sleadership in early clinical development. As biopharmaceutical companies havebeen conducting more Phase I and Proof of Concept studies with increasingcomplexity, PAREXEL has been well positioned to meet their needs. In thisregard, we are a top provider of expertise-based Phase I services and havemore than 550 beds, which is among the largest capacities worldwide," saidHerman Scholtz, M.D., Head of International Clinical Pharmacology, PAREXEL."Clients rely on our in-depth medical and therapeutic expertise to help themconduct rigorous clinical trials in order to identify and select promising newcompounds." Dr. Scholtz added, "Long before hospital-based units became anindustry best practice, PAREXEL saw the benefit of that approach and locatedour clinical pharmacology research units in hospitals in order to provide asafe, high-quality environment for early phase development activities."
Advertisement
In Baltimore, PAREXEL's Clinical Pharmacology Research Unit has beenexpanding capabilities and capacity for client programs since 2001, when theunit opened. With its most recent expansion, the unit now has 90 beds,representing the largest such facility in the region. The unit has deepspecialization in many clinical areas such as vaccine and immunology,pulmonary, and oncology studies, and provides leading offerings such asadvanced neuroimaging and radiochemistry capabilities using Positron EmissionTomography (PET).
The PAREXEL Clinical Pharmacology Research Unit in London, establishedmore than 15 years ago, has been expanded to a 64-bed capacity. The unit hasexperience with all types of Phase I studies, including pharmacokinetic andpharmacodynamic studies, and has the ability to conduct PET studies, as well.Clinical pharmacology experts based in the London unit have experience acrossa broad range of therapeutic areas, with extensive expertise in conductingcardiology and respiratory studies. The unit has a dedicated respiratorylaboratory, and is outfitted with cardiac telemetry and electrocardiogram(ECG) monitoring.
PAREXEL has two long-established Clinical Pharmacology Research Units inBerlin. With the recent expansion, the units now have 160 total beds. The twosites have dedicated medical teams that utilize identical equipment andsystems to assure harmonized procedures and workflow. The units have sleepresearch capabilities and a sleep laboratory, as well as extensive expertisein cardiovascular, central nervous system, respiratory, dermatology,metabolism and endocrine, and infectious disease studies.
In addition to the units noted above, PAREXEL also has clinicalpharmacology research units in San Diego and Los Angeles in the United States,and in Bloemfontein and George, South Africa. PAREXEL also provides earlyclinical development programs through a joint venture arrangement withSynchron Research based in India. The Company's northern and southernhemisphere locations provide seasonal benefits for year-round studies, as wellas access to specialized patient populations and the ability to conduct multi-site studies for parallel clinical development. All of the research units areequipped with advanced, state-of-the-art technologies, and utilize PAREXEL'sproprietary ClinBase(TM) technology, an electronic data capture andinformation management system that is fully validated and 21CFR part 1
